Posted by SLS on July 5, 2021, at 11:19:02
In reply to Re: Short-Course Zuranolone Looks Promising for MDD, posted by TriedEveryMedication on July 2, 2021, at 10:07:34
> "A potential limitation of brexanolone is the estimated cost of $34,000 for one continuous infusion,"
Brexanolone (Zulresso) is approved as an I.V. drug, and is approved for postpartum depression only.Zurazolone is to be taken orally. This is the drug that I had been waiting for a few years. Sage Therapeutic (and Biogen) have conducted a Phase III clinical trial that reports a favorable therapeutic effect. It looks like zuranolone might be approved for postpartum depression, major depressive disorder, and bipolar depression.
- ScottSome see things as they are and ask why.
I dream of things that never were and ask why not.The only thing necessary for the triumph of evil is that good men do nothing.
poster:SLS
thread:1115627
URL: http://www.dr-bob.org/babble/20210418/msgs/1115791.html